

SCHOOL OF PHARMACY

3RD QUARTER | SEPTEMBER 2023

MINER RX NUGGET

Updates for the preceptors of the University of Texas at El Paso School of Pharmacy

Contents

ANNOUNCEMENTSP.2	FEATURED ARTICLEP.5
CORE ELMS CORNERP.3	NEW ADDITIONS TO UTEP SOPP.8

UTEP White Coat Ceremony Class of 2027



Calendar:

Oct. 15-21 - National Pharmacy Week

Nov. 14th - PET Quarterly Meeting & Preceptor Recognition Dinner

Nov. 23-24th - Thanksgiving Holiday - University Closed

Dec. 25-Jan. 1st - Christmas Holiday Break - University Closed

Upcoming Rotation Dates:

2023 Fall IPPE

Aug. 28 - Dec. 10: Week 1-15

2023-24 APPE

Sep. 25 - Nov. 3: APPE 4


Nov. 6 - Dec. 15: APPE 5

Jan. 8 - Feb. 16: APPE 6

Feb. 19 - Mar. 29: APPE 7

Apr. 1 - May 10: APPE 8

Update your calendar: Send us your events!



Announcements

Join us at the UTEP Homecoming Pre-Game Party!

The first ten pharmacists to contact us will receive a complimentary <u>Homecoming Pre-Game</u> AND <u>Football Game</u> entry ticket for

them and one guest!

Contact us at exedpharmacy@utep.edu



CORE ELMS Corner

<u>Preceptor Resources in the CORE ELMS Document</u> <u>Library</u>

The CORE ELMS Document Library houses a wealth of information which serve as resources for Preceptors before, during, and after student rotations. Some documents are accessible directly from the CORE ELMS Homepage however selecting the "**Document Library**" option from the left hand menu will present entirety of the documents within.

Below is a list of folders found within the **"Document Library"** and some of the most useful documents within each section.

UTEP New Preceptor Orientation

The "UTEP New Preceptor Orientation" section assists new preceptors in familiarizing themselves with the UTEP School of Pharmacy curriculum, the CORE ELMS portal, Preceptor Rules and Responsibilities along with other topics pertinent to student rotations. The Office of Experiential Education has made available a list of modules which serve to orient preceptors before taking a student on rotation. We encourage all new and current preceptor to view the modules as they provide answers for many most commonly asked questions.

UTEP New Preceptor Orientation (8 Files)	
VIEW	TITLE
VIEW	FERPA Compliance Orientation Module All UTEP SOP Preceptors must review the Family Educational Rights and Privacy Act (FERPA) as they work with student records.
VIEW	Preceptor Orientation Module-1 "Introduction to UTEP School of Pharmacy and Curriculum." You may also view a Youtube presentation of this document. https://youtu.be/L2rp23KL
VIEW	Preceptor Orientation Module-2 "Performance Assessment and Forms Overview." You may also view a Youtube presentation of this document, https://youtu.be/DF2t3xsWUkl
VIEW	Preceptor Orientation Module-3 "Review of CORE ELMS Learning Tools" You may also view a Youtube presentation of this document. https://youtu.be/GRxuOPH2DYg
VIEW	Preceptor Orientation Module-4 "Preceptor and Student Rules and Responsibilities." You may also view a Youtube presentation of this document. https://youtu.be/G13Z0SXwtek
VIEW	Preceptor Orientation Module-5 "Teaching Methods." You may also view a Youtube presentation of this document. https://youtu.be/7qvIL-tXnZY
VIEW	Preceptor Orientation Module-6 Residency Program - Preceptor Orientation 2022
VIEW	UTEP Preceptor Orientation Completion Questionnaire-REQUIRED Please complete this questionnaire after reviewing the New Preceptor Orientation modules above to signify completion of the onboarding process


CORE ELMS Corner

<u>Preceptor Resources in the CORE ELMS Document</u> <u>Library</u>

Preceptor Resources


The "Preceptor Resources" section is an ever expanding folder with information ranging from free Preceptor CE course to annual publication of the UTEP OEE Handbook. A few of the most useful documents are;

- CEImpact: Preceptor CE Education
- Incident Reporting Workflow for Preceptors
- Sharing/Sending Student Evaluations to Other Preceptors
- UPDATE: Evaluating UTEP Pharmacy Students in IPPE's and APPE's
- UTEP Library Resources for Preceptors
- UTEP Office of Experiential Education Handbook 2023-24



APPE and IPPE Rotation Documents

The document library also provides a dedication folder for each curriculum containing course syllabi and assignments for each rotation type. These folders are available to both preceptors and students to ensure consistency and clarity of rotation expectations.





Featured Article

FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

"Today, the U.S. Food and Drug Administration took action approving and authorizing for emergency use updated COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death. Today's actions relate to updated mRNA vaccines for 2023-2024 manufactured by ModernaTX Inc. and Pfizer Inc. Consistent with the totality of the evidence and input from the FDA's expert advisors, these vaccines have been updated to include a monovalent (single) component that corresponds to the Omicron variant XBB.1.5."

What You Need to Know

- Individuals 5 years of age and older regardless of previous vaccination are eligible to receive a single dose of an updated mRNA COVID-19 vaccine at least 2 months since the last dose of any COVID-19 vaccine.
- Individuals 6 months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of an updated mRNA COVID-19 vaccine (timing and number of doses to administer depends on the previous COVID-19 vaccine received).
- Unvaccinated individuals 6 months through 4 years of age are eligible to receive three doses of the updated authorized Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated authorized Moderna COVID-19 Vaccine.
- The FDA is confident in the safety and effectiveness of these updated vaccines and the agency's benefit-risk assessment demonstrates that the benefits of these vaccines for individuals 6 months of age and older outweigh their risks.
- Individuals who receive an updated mRNA COVID-19 vaccine may experience similar side effects as those reported by individuals who previously received mRNA COVID-19 vaccines as described in the respective prescribing information or fact sheets.
- The updated vaccines are expected to provide good protection against COVID-19 from the currently circulating variants. Barring the emergence of a markedly more virulent variant, the FDA anticipates that the composition of COVID-19 vaccines may need to be updated annually, as is done for the seasonal influenza vaccine.
- The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices will meet tomorrow (Sept. 12), to discuss clinical recommendations on who should receive an updated vaccine, as well as further considerations for specific populations such as immunocompromised and older individuals.
- Manufacturers have publicly announced that the updated vaccines would be ready this
 fall, and the FDA anticipates that the updated vaccines will be available in the near
 future.



Featured Articles (cont.)

"Vaccination remains critical to public health and continued protection against serious consequences of COVID-19, including hospitalization and death," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research. "The public can be assured that these updated vaccines have met the agency's rigorous scientific standards for safety, effectiveness, and manufacturing quality. We very much encourage those who are eligible to consider getting vaccinated."

The updated mRNA vaccines are each approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age. As part of today's actions, the bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.

Data Supporting the Updated mRNA COVID-19 Vaccines (2023-2024 Formula)

The mRNA COVID-19 vaccines approved and authorized today are supported by the FDA's evaluation of manufacturing data to support the change to the 2023-2024 formula and non-clinical immune response data on the updated formulations including the XBB.1.5 component.

- The updated mRNA vaccines are manufactured using a similar process as previous formulations. In studies that have been recently conducted, the extent of neutralization observed by the updated vaccines against currently circulating viral variants causing COVID-19, including EG.5 and BA.2.86, appears to be of a similar magnitude to the extent of neutralization observed with prior versions of the vaccines against corresponding prior variants against which they had been developed to provide protection. This suggests that the vaccines are a good match for protecting against the currently circulating COVID-19 variants.
- The benefit-risk profile of previously authorized and approved mRNA COVID-19 vaccines is well understood as these vaccines have been administered to hundreds of millions of people in the United States.

Based on an evaluation of the totality of the evidence, the benefit-risk profile is favorable for individuals 6 months of age and older to receive an updated COVID-19 mRNA vaccine. Although serious outcomes from COVID-19 are less common in younger individuals, they do occur, and it has been demonstrated that recently receiving a COVID-19 vaccine reduces the risk of such serious outcomes.

Featured Articles (cont.)

Additional Details on Today's Actions

Specifically, today's actions include:

- Approval of Comirnaty (COVID-19 Vaccine, mRNA) to include the 2023-2024 formula, and a change to a single dose for individuals 12 years of age and older. Comirnaty was previously approved as a two-dose series for individuals 12 years of age and older.
- Approval of Spikevax (COVID-19 Vaccine, mRNA) to include the 2023-2024 formula, a change to a single dose for individuals 18 years of age and older, and approval of a single dose for individuals 12 through 17 years of age. Spikevax was previously approved as a two-dose series for individuals 18 years of age and older.
- Authorization of Moderna COVID-19 Vaccine for emergency use in individuals 6 months through 11 years of age to include the 2023-2024 formula and lower the age eligibility for receipt of a single dose from 6 years to 5 years of age. Additional doses are also authorized for certain immunocompromised individuals ages 6 months through 11 years, as described in the fact sheets.
- Authorization of Pfizer-BioNTech COVID-19 Vaccine for emergency use in individuals 6
 months through 11 years of age to include the 2023-2024 formula. Additional doses are
 also authorized for certain immunocompromised individuals ages 6 months through 11
 years, as described in the fact sheets.

The approval of Comirnaty (COVID-19 Vaccine, mRNA) (2023-2024 Formula) was granted to BioNTech Manufacturing GmbH. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) was issued to Pfizer Inc.

The approval of Spikevax (COVID-19 Vaccine, mRNA) (2023-2024 Formula) was granted to ModernaTX Inc. and the EUA amendment for the Moderna COVID-19 Vaccine (2023-2024 Formula) was issued to ModernaTX Inc."





New Additions to UTEP School of Pharmacy



Mandi Bever, PharmD, MBA Clinical Assistant Professor



Andre Montes, PharmD, BCPP Clinical Instructor



Nicole Davis, PharmD, BCPS, BCOP Clinical Instructor



Calling for 2024-25 IPPE/APPE Availability



We are currently calling out for 2024-25 IPPE/APPE Availability. Summer IPPE Community/Hospital rotations start on May 27th 2024 until August 16th 2024. APPE rotations start on May 20th 2024 until May 9th 2025.

Please notify the OEE department at exedpharmacy@utep.edu if you are available to take students. We will be happy to assist in collecting your availability.

Thank you in advance for supporting our students!



This is a quarterly publication of the UTEP Office of Experiential Education/Preceptor Excellence Team.

We'd love to hear from YOU - article ideas, events, awards/achievements/celebrations, or interested in becoming more involved.

Contact the OEE/PET: exedpharmacy@utep.edu